Table 3.
Initial diagnosis and current period lab measurements of glycaemic control per treatment strategy
| Variable | Initial diagnosis | Current period | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Treatment Strategy | Treatment Strategy | P | |||||||
| All | A | B | C | All | A | B | C | ||
| Patients n (%) | 1189 (100%) | 722 (60.7%) | 334 (28.1%) | 133 (11.2%) | 1189 (100%) | 241 (20.3%) | 478 (40.2%) | 470 (39.5%) | |
| Full analysis set, n | 572 (100%) | 359 (62.8%) | 151 (26.4%) | 62 (10.8%) | 1120 (100%) | 225 (20.1%) | 452 (40.4%) | 443 (39.6%) | |
| HbA1c % | |||||||||
| Median (IQR) | 7.8 (7.0–9.0) | 7.5 (6.8–8.2) | 8.6 (7.7–10.0) | 10.0 (8.5–11.7) | 6.9 (6.3–7.5) | 6.4 (6.0–7.0) | 6.7 (6.3–7.2) | 7.3 (6.7–8.0) | < 0.001b |
| Mean ± SD | 8.4 ± 1.4 | 7.5 ± 1.6 | 8.3 ± 1.1 | 9.3 ± 2.2 | 7.1 ± 1.2 | 6.6 ± 1.0 | 6.9 ± 1.1 | 7.5 ± 1.2 | |
| Adjustedc mean ± SD | 8.1 ± 0.2 | 8.3 ± 0.1 | 8.5 ± 0.1 | 7.0 ± 0.1 | 7.0 ± 0.1 | 7.2 ± 0.1 | 0.771 | ||
| < 6.5% | 42 (7.0%) | 38 (10.0%) | 3 (1.0%) | 1 (1.0%) | 339 (30.0%) | 115 (51.1%) | 159 (35.2%) | 65 (14.7%) | < 0.001a |
| [6.5–7.0%) | 73 (12.0%) | 65 (18.0%) | 8 (5.0%) | 0 (0%) | 259 (23.0%) | 52 (23.1%) | 115 (25.4%) | 92 (20.7%) | |
| < 7.0% | 115 (19.0%) | 103 (28.0%) | 11 (6.0%) | 1 (1.0%) | 598 (53.0%) | 167 (74.2%) | 274 (60.6%) | 157 (35.4%) | |
| [7.0–7.5%) | 92 (16.0%) | 73 (20.0%) | 16 (10.0%) | 3 (4.0%) | 218 (19.0%) | 34 (15.1%) | 94 (20.8%) | 90 (20.3%) | |
| [7.5–8.0%] | 119 (20.0%) | 81 (22.0%) | 30 (19.0%) | 8 (12.0%) | 149 (13.0%) | 14 (6.2%) | 42 (9.3%) | 93 (21.0%) | |
| > 8.0% | 246 (43.0%) | 102 (28.0%) | 94 (62.0%) | 50 (80.0%) | 155 (13.0%) | 10 (4.5%) | 42 (9.3%) | 103 (23.3%) | |
| FPG mg/dl | |||||||||
| Median (IQR) | 177 (142–234) | 160 (135–200) | 200 (160–259) | 240 (186–350) | 126 (110–150) | 120 (107–135) | 126 (110–150) | 130 (111–161) | < 0.001b |
| Mean ± SD | 201 ± 85 | 179 ± 63 | 221 ± 82 | 280 ± 133 | 136 ± 42 | 126 ± 32 | 135 ± 41 | 141 ± 46 | |
| Adjustedc mean ± SD | 189.4 ± 6.9 | 201.1 ± 4.7 | 206.3 ± 5.1 | 134.8 ± 3.0 | 133.1 ± 2.0 | 138.6 ± 2.1 | 0.180 | ||
| Median (IQR) | NA | NA | NA | NA | 144 (130–160) | 152 (138–178) | 170 (145–200) | 144 (130–160) | < 0.001b |
| Adjustedc mean ± SD | NA | NA | NA | NA | 163.2 ± 3.7 | 166.0 ± 2.5 | 169.6 ± 2.6 | 0.375 | |
aChi – square independence test,
bKruskal Wallis test
cMean values adjusted for age, duration of diabetes, body mass index and family history of diabetes
Kruskal Wallis post-hoc pairwise comparisons between groups
•HbA1c % vs Treatment Group:
Treatment Group A vs Treatment Group B: p < 0.001.
Treatment Group A vs Treatment Group C: p < 0.001.
Treatment Group C vs Treatment Group B: p < 0.001
•FBG vs Treatment Group:
Treatment Group A vs Treatment Group B: p = 0.003
Treatment Group A vs Treatment Group C: p < 0.001.